Invention Grant
- Patent Title: Fused pentacyclic imidazole derivatives as modulators of TNF activity
-
Application No.: US16086408Application Date: 2017-03-31
-
Publication No.: US10654861B2Publication Date: 2020-05-19
- Inventor: Michael Louis Robert Deligny , Jag Paul Heer , Jean Keyaerts , Luce Elsa Lepissier , Martin Alexander Lowe
- Applicant: UCB Biopharma SRL , Sanofi
- Applicant Address: BE Brussels
- Assignee: UCB Biopharma SRL
- Current Assignee: UCB Biopharma SRL
- Current Assignee Address: BE Brussels
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@170c79d9
- International Application: PCT/EP2017/057767 WO 20170331
- International Announcement: WO2017/167994 WO 20171005
- Main IPC: C07D487/18
- IPC: C07D487/18 ; C07D487/04

Abstract:
A series of substituted fused pentacyclic benzimidazole derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Public/Granted literature
- US20190100525A1 Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity Public/Granted day:2019-04-04
Information query